FILE 'HOME' ENTERED AT 10:42:08 ON 20 AUG 2008

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE ENTRY 0.21

TOTAL SESSION 0.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:42:21 ON 20 AUG 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COYNIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Aug 2008 VOL 149 ISS 8 FILE LAST UPDATED: 19 Aug 2008 (20080819/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s 165537-73-5 and clopidogrel REG1stRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress... Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L2 14 L1

T. 3

2230 CLOPIDOGREL 2 L2 AND CLOPIDOGREL

=> d 1-2 ibib abs hitstr

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:301861 CAPLUS

DOCUMENT NUMBER: 142:329857

TITLE: Synergistic combination of an anti-atherothrombotic

agent and a platelet aggregation inhibitor
INVENTOR(S): Cloarec, Blanchard Laure; Corda, Stefano; Lerond,

INVENTOR(S). Cloarec,

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: Fr. Demande, 10 pp.

CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French

LANGUAGE: Fre

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PRI

165537-73-5

R 2860436				A1 20050408														
2860436				B1 20060120														
									AU 2	004-		20041001						
2004	2777	34		B2		2007	0524											
CA 2540062				A1		2005	0414					20041001						
2005	0325	33		A1		2005	0414		WO 2	004-	FR24	89		2	0041	001		
₩:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,		
	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,		
	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,		
	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,		
	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,		
	TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW		
RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,		
	AZ,	BY,	KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,		
	SI,	SK,	TR,	BF,	ΒJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,		
R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,		
	IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	PL,	SK,		
1859	902			A		2006	1108		CN 2	004-	20041001							
2004	0150	43		A		2006	1212		BR 2004-15043						20041001			
2007	5074	75		T		2007	0329		JP 2006-530412						20041001			
2006	DN01	446		A		2007	0803		IN 2006-DN1446						20060317			
20070054934 A1						2007	0308		US 2006-574119						20060330			
2006	PA03	713		A		2006	0614		MX 2	006-	PA37	13		2	0060	403		
7822	46			B1		2007	1205		KR 2	006-	7080	71		20060426				
2006	0019	44		A		2006	0502											
Y APP	LN.	INFO	. :						FR 2	003-	1159	5		A 2	0031	003		
									WO 2									
	2860 2004 2004 2005 W: RW: 1677 R: 1859 2004 2007 2006 2007 7822 2006	2860436 2860436 20042777 20042777 20042777 20050325 W: AC, KM, GE, KM, GE, KM, GE, KM, GE, KM, GE, SIN, 1677779 R: AT, 1859902 20040150 2005001 20060001 20060003 782246	2860436 2860436 2004277734 2004277734 2004277734 2004277734 2004277734 2005032533 W: AE, AG, CN, CO, GE, GH, LK, LR, NO, NZ, LY, LY, LY, LY, LY, LY, LY, LY, LY, LY	2860436 2860436 2004277734 2004277734 2004277734 2540062 2005032533 W: AE, AG, AL, CM, CO, CR, GE, GH, GM, LK, LR, LS, NO, NZ, OM, AZ, BY, KG, EE, ES, FI, SI, SK, TR, SI, SI, SI, SI, SI, SI, SI, SI, SI, SI	2860436 A1 2860436 B1 2860436 B1 2004277734 A1 2004277734 B2 2540062 A1 W: AE, AG, AL, AM, CN, CO, CR, CO, GR, CO, GR, CO, GR, CO, TJ, TM, TN, TR, RW: BW, GH, GM, KE, AZ, BY, KG, KZ, EE, ES, FIT, FR, SI, SK, TR, BF, SK, TR, SK, TR	2860436 A1 2860436 B1 2004277734 A1 2004277734 B2 2540062 A1 W: AE, AG, AL, AM, AT, CN, CO, CR, CU, CZ, GE, GH, GM, HR, HU, LK, LR, LS, LT, LU, NO, NZ, OM, PG, PH, TM, TM, TM, TM, TM, TM, TM, TM, TM, TM	2860436 81 2006 2860436 81 2006 2860436 81 2006 2004277734 82 2007 2540062 81 2005 2005032533 81 2005 2005032533 81 2005 2005032533 81 2005 2005032531 81 2005 2005032531 81 2005 2005032531 81 2005 2005032531 81 2005 2005032531 81 2005 2005 2005032531 81 2005 2005 2005032531 81 2005 2005 2005032531 81 2005 2005 2005032531 81 2005 2005032531 81 2005 2005032531 81 2005 2005032531 81 2005 2005032531 81 2005 2005032531 81 2005 2005032531 81 2005 2005032531 81 2005 2005032531 81 2005 2005032531 81 2005 2005032531 81 2005 2005032531 81 2005 2005032531 81 2005 200503713 81 2006 2006203713 81 2007 20062001944 81 2007 2006001944 81 2007	2860436	2860436 A1 20050408 2860436 B1 20060120 2004277734 A1 20050414 2004277734 B2 20070524 2540062 A1 20050414 W: AE, AG, AL, AM, AT, AU, AZ, BA, CN, CO, CR, CU, CZ, DE, DK, DM, GE, GH, GK, HR, HU, ID, IL, IN, NO, NZ, OM, PG, PH, LP, FT, RO, NT, TJ, TM, TN, TT, TZ, UA, UG, RW: BW, GH, GH, KE, LS, MW, MZ, NA, AZ, BY, KG, KZ, MD, RU, TJ, TM, EE, ES, FI, FR, GB, GR, HU, IE, SI, SK, TR, BF, BJ, CF, CG, CI, SN, TD, TG 1677779 A1 20060712 R: AT, BE, CH, DE, DK, ES, FR, GB, IE, SI, SI, TL, LV, FI, RO, MK, CY, 1859902 A2 20065N0144 A2 20070803 20070054934 A1 20070803	2860436 B1 20050408 FR 2 2860436 B1 20060120 2004277734 B2 20070524 2540062 A1 20050414 A2 2 205032533 A1 20050414 CA 2 20503253 A1 20050414 CA 2 2050503253 A1 20050414 CA 2 2050503253 A1 20050414 CA 2 205050414 A1 20070308 CM 2 200667045 A 2006614 MX 2 20066001446 A 20070308 US 2 20060001446 A 20070308 US 2 20066001444 A 20070308 US 2 20060001446 B1 20070205 KR 2	2860436	2860436	2860436	2860436	2860436	2860436 B1 20060120 2004277734 A1 20050141 AU 2004-277734 20041 2004277734 B2 20070524 2540062 A1 20050414 CA 2004-2540062 205032533 A1 20050414 W0 2004-F82489 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, LK, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, NA, TJ, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, RN, BW, BW, KE, LS, MM, AW, NA, NA, SS, SS, ES, SK, KK, LS, LS, KT, RS, BF, BR, BR, BR, BR, BR, BR, BR, BR, BR, BR		

AB A new synergistic combination of an anti-atherothrombotic agent and a platelet aggregation inhibitor is claimed. Combination of 75 mg clopidogrel and 10 mg of 6-[[(4-chlorophenyl]sulfonyl]amino]-5,6,7,8-tetrahydro-2-methyl-1-naphthalenepropanoic acid administered orally to volunteers for 3 days decreased the platelet aggregation by 62% as compared to 11% for clopidogrel alone.

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(synergistic combination of anti-atherothrombotic agent and platelet aggregation inhibitor)

RM 165537-73-5 CAPLUS

CN 1-Naphthalenepropanoic acid, 6-[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8tetrahydro-2-methyl- (CA INDEX NAME)

HO2C-CH2-CH2 Ме

REFERENCE COUNT: THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2004:405522 CAPLUS

DOCUMENT NUMBER: 141:374569

TITLE: Antithrombotic effects of S 18886, a novel orally

active thromboxane A2 receptor antagonist AUTHOR(S): Osende, J. I.; Shimbo, D.; Fuster, V.; Dubar, M.;

Badimon, J. J.

CORPORATE SOURCE: Cardiovascular Biology Research Laboratory and Cardiovascular Institute, Mount Sinai School of

Medicine, New York City, NY, USA

SOURCE: Journal of Thrombosis and Haemostasis (2004), 2(3), 492-498

CODEN: JTHOA5; ISSN: 1538-7933

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

Platelet activation and thrombus formation play a critical role in the onset of acute coronary syndromes. Thromboxane A2 (TxA2) is among the different chemical modulators released by activated platelets. TxA2 is considered one of the most powerful agonists for platelet activation. In addition, TxA2 exerts a vasoconstrictor effect by serving as an agonist of the thromboxane receptor (TP) on the vascular smooth muscle cell membranes. The putative effect of TxA2 on thrombosis is demonstrated by the clin. effectiveness of acetylsalicylic acid (ASA) in the prevention of acute coronary syndromes. Among the clin, used antiplatelet agents, clopidogrel has shown to be slightly more effective than ASA in the prevention of atherothrombotic events in patients with peripheral arterial disease, and is one of the most widely used after aspirin. The aims of the study were to study the antithrombotic effects of escalating doses of the TP-receptor antagonist, S 18886 and to compare its effects with those achieved by the administration of ASA (5 mg kg-1 day-1), and clopidogrel (3 mg kg-1 day-1). The study was undertaken at high and low shear rate conditions using the Badimon perfusion chamber in a porcine model. Antithrombotic effects were assessed as changes on platelet and fibrin(ogen) deposition. The doses of 30 and 100 μg kg-1 day-1 were selected based on a previous platelet aggregation study. S

18886 shows a dose-dependent antithrombotic response. The dose of S-100 develops similar antithrombotic effects to those of clopidogrel and superior to those of aspirin. The antithrombotic effects were statistically significant at both studied shear rate conditions. Therefore, the orally active TP-receptor antagonist, S 18886, appears to be a new and effective agent to prevent atherothrombotic complications. 165537-73-5, S 18886

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(TP-receptor antagonist S 18886 at 100µg/kg/day exerted dose-dependent antithrombotic effect similar to clopidogrel but superior to ASA at high, low shear rates as evident by inhibition of platelet and fibrinogen deposition in pig model)

RN 165537-73-5 CAPLUS

CN 1-Naphthalenepropanoic acid, 6-[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8tetrahydro-2-methyl- (CA INDEX NAME)

REFERENCE COUNT:

33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY 16.10	SESSION 17.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.60	-1.60

FILE 'REGISTRY' ENTERED AT 10:44:11 ON 20 AUG 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by  ${\tt InfoChem.}$ 

STRUCTURE FILE UPDATES: 19 AUG 2008 HIGHEST RN 1042061-07-3 DICTIONARY FILE UPDATES: 19 AUG 2008 HIGHEST RN 1042061-07-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when

conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> s clopidogrel/cn
L4
             1 CLOPIDOGREL/CN
=> d
    ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
T. 4
RN
    113665-84-2 REGISTRY
ED
     Entered STN: 02 Apr 1988
CN
     Thieno[3,2-c]pyridine-5(4H)-acetic acid, a-(2-chlorophenyl)-6,7-
     dihydro-, methyl ester, (aS)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
    Thieno[3,2-c]pyridine-5(4H)-acetic acid, a-(2-chlorophenyl)-6,7-
    dihydro-, methyl ester, (S)-
OTHER NAMES:
    (+)-(S)-Clopidogrel
CN
CN
    (S)-(+)-Methyl (2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-
     vl)acetate
CN
    (S)-Clopidogrel
CN
    (S)-Methyl \alpha-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl)-\alpha-
     (o-chlorophenyl)acetate
CN
    Clopidogrel
CN
    Methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-
     vl)acetate
    SR 25990
CN
CN
    Zyllt
FS
    STEREOSEARCH
MF
    C16 H16 C1 N O2 S
CI
SR
     World Health Organization (WHO)
                ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
```

(\*File contains numerically searchable property data)

CA, CABA, CAPLUS, CASREACT, CENB, CHEMCATS, CIN, CSCHEM, EMBASE, HSDB\*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, PATDPASPC, PROMT, PROUSDDR, PS, RTECS\*, SCISEARCH, SYNTHLINE, TOXENTER, USAN,

Absolute stereochemistry. Rotation (+).

USPAT2, USPATFULL

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1642 REFERENCES IN FILE CA (1907 TO DATE)
23 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1656 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
CA SUBSCRIBER PRICE

SINCE FILE
ENTRY
SESSION
0.00
-1.60
-1.60
-1.60
-1.60

FILE 'CAPLUS' ENTERED AT 10:45:18 ON 20 AUG 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Aug 2008 VOL 149 ISS 8 FILE LAST UPDATED: 19 Aug 2008 (20080819/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s 165537-73-5 and 113665-84-2 REG1stRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress... Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L6 1656 L5

## REG1stRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress... Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L8 14 L7

L9 2 L8 AND L6

## => d 1-2 ibib abs hitstr

L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:301861 CAPLUS

DOCUMENT NUMBER: 142:329857

TITLE: Synergistic combination of an anti-atherothrombotic

agent and a platelet aggregation inhibitor

INVENTOR(S): Cloarec, Blanchard Laure; Corda, Stefano; Lerond,

Laurence

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: Fr. Demande, 10 pp.

CODEN: FRXXBL
DOCUMENT TYPE: Patent

LANGUAGE: French FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	ENT				KIND DATE				APPLICATION NO.							DATE			
FR 2860436					A1 20050408						003-	2	20031003						
FR 2860436					B1 20060120														
AU 2004277734					A1 20050414					AU 2	2	0041	001						
AU	AU 2004277734					B2 20070524													
CA	2540	062		A1 20050414					CA 2	004-	2	20041001							
WO	WO 2005032533					A1 20050414				WO 2	004-		2						
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,		
		CN,	co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,		
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,		
		LK.	LR.	LS.	LT.	LU,	LV.	MA.	MD.	MG.	MK.	MN.	MW.	MX.	MZ.	NA.	NI.		
		NO.	NZ.	OM.	PG.	PH.	PL,	PT.	RO.	RU.	sc.	SD.	SE.	SG.	SK.	SL,	SY.		
							TZ,												
	RW:						MW.												
		AZ.	BY.	KG.	KZ.	MD.	RU,	TJ.	TM.	AT.	BE.	BG.	CH.	CY.	CZ.	DE.	DK.		
							GR,												
							CF,												
			TD.			- /							~ '						
EP	1677			A1 20060712					EP 2	004-	20041001								

	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	PL,	SK,	HR
CN	1859	902			A		2006	1108		CN 2	004-	8002	8356		2	0041	001	
BR	2004	0150	43		A		2006	1212	1	BR 2	004-	15043	3		2	0041	001	
JP	2007	5074	75		T		2007	0329		JP 2	006-	5304:	12		2	0041	001	
IN	2006	DN01	446		A		2007	0803		IN 2	006-	DN14	46		2	0060	317	
US	2007	0054	934		A1		2007	0308	1	US 2	006-	5741:	19		2	0060	330	
MX	2006	PA03	713		A		2006	0614	1	MX 2	006-	PA37:	13		2	0060	403	
KR	7822	46			B1		2007	1205	1	KR 2	006-	7080	71		2	0060	426	
NO	2006	0019	44		A		2006	0502	1	NO 2	006-	1944			2	0060	502	
PRIORIT	Y APF	LN.	INFO	. :					1	FR 2	003-	1159	5	7	A 2	0031	003	
									1	70 2	004-	FR241	89	Ţ	1 2	0041	001	
								-										

- AB A new synergistic combination of an anti-atherothrombotic agent and a platelet aggregation inhibitor is claimed. Combination of 75 mg clopidogrel and 10 mg of 6-[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-2-methyl-1-naphthalenepropanoic acid administered orally to volunteers for 3 days decreased the platelet aggregation by 62% as compared to 11% for clopidogrel alone.
- IT 113665-84-2, Clopidogrel 165537-73-5
  - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
    - (synergistic combination of anti-atherothrombotic agent and platelet aggregation inhibitor)
- RN 113665-84-2 CAPLUS
- CN Thieno [3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

- RN 165537-73-5 CAPLUS
- CN 1-Naphthalenepropanoic acid, 6-[[(4-chloropheny1)sulfony1]amino]-5,6,7,8tetrahydro-2-methyl- (CA INDEX NAME)

REFERENCE COUNT:

5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:405522 CAPLUS

DOCUMENT NUMBER: 141:374569

TITLE: Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist

AUTHOR(S): Osende, J. I.; Shimbo, D.; Fuster, V.; Dubar, M.;

Badimon, J. J.

CORPORATE SOURCE: Cardiovascular Biology Research Laboratory and Cardiovascular Institute, Mount Sinai School of

Medicine, New York City, NY, USA

SOURCE: Journal of Thrombosis and Haemostasis (2004), 2(3), 492-498

CODEN: JTHOA5; ISSN: 1538-7933

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

Platelet activation and thrombus formation play a critical role in the onset of acute coronary syndromes. Thromboxane A2 (TxA2) is among the different chemical modulators released by activated platelets. TxA2 is considered one of the most powerful agonists for platelet activation. In addition, TxA2 exerts a vasoconstrictor effect by serving as an agonist of the thromboxane receptor (TP) on the vascular smooth muscle cell membranes. The putative effect of TxA2 on thrombosis is demonstrated by the clin. effectiveness of acetylsalicylic acid (ASA) in the prevention of acute coronary syndromes. Among the clin, used antiplatelet agents, clopidogrel has shown to be slightly more effective than ASA in the prevention of atherothrombotic events in patients with peripheral arterial disease, and is one of the most widely used after aspirin. The aims of the study were to study the antithrombotic effects of escalating doses of the TP-receptor antagonist, S 18886 and to compare its effects with those achieved by the administration of ASA (5 mg kg-1 day-1), and clopidogrel (3 mg kg-1 day-1). The study was undertaken at high and low shear rate conditions using the Badimon perfusion chamber in a porcine model. Antithrombotic effects were assessed as changes on platelet and fibrin(ogen) deposition. The doses of 30 and 100 µg kg-1 day-1 were selected based on a previous platelet aggregation study. S 18886 shows a dose-dependent antithrombotic response. The dose of S-100 develops similar antithrombotic effects to those of clopidogrel and superior to those of aspirin. The antithrombotic effects were statistically significant at both studied shear rate conditions. Therefore, the orally active TP-receptor antagonist, S 18886, appears to be a new and effective agent to prevent atherothrombotic complications.

IT 165537-73-5, S 18886

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(TP-receptor antagonist S 18886 at  $100\mu g/kg/day$  exerted dose-dependent antithrombotic effect similar to clopidogrel but superior to ASA at high, low shear rates as evident by inhibition of platelet and fibrinogen deposition in pig model)

RN 165537-73-5 CAPLUS

CN 1-Naphthalenepropanoic acid, 6-[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8tetrahydro-2-methyl- (CA INDEX NAME)

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>
Me
NH-S

IT 113665-84-2, Clopidogrel

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

- (Biological study); USES (Uses) (oral TP-receptor antagonist S 18886 at 100µg/kg/day exerted dose-dependent antithrombotic effect similar to clopidogrel at high, low shear rates as evident by inhibition of platelet and fibrinogen deposition in pig model)
- RN 113665-84-2 CAPLUS
- CN Thieno[3,2-c]pyridine-5(4H)-acetic acid,  $\alpha$ -(2-chlorophenyl)-6,7-dihydro-, methyl ester,  $(\alpha S)$  (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

REFERENCE COUNT:

33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD, ALL CITATIONS AVAILABLE IN THE RE FORMAT